Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251027 · ClinicalTrials.gov registry record · NA
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
A NA study of Glioblastoma and WHO Grade III Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03251027: Active NA study of Glioblastoma and WHO Grade III Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
NCT03251027 is a NA study of Glioblastoma and WHO Grade III Glioma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 100 participants, roughly in line with the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03251027, a NA study of Glioblastoma and WHO Grade III Glioma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
Primary Outcome
Will assess the impact of intensity-modulated stereotactic radiotherapy (IM-SRT) on the incidence of wound infection, or wound dehiscence.
Conditions Studied
Interventions
- RADIATION Intensity-Modulated Radiation Therapy
- OTHER Quality-of-Life
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What the registry record for NCT03251027 still lists
NCT03251027 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Intensity-Modulated Radiation Therapy is the first listed.
NCT03251027 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03251027 about?
NCT03251027 is a clinical study titled "Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma". This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to n...
What is the current status of trial NCT03251027?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2017-07-17. Estimated completion is 2027-12-31.
What conditions does trial NCT03251027 study?
This clinical trial studies the following conditions: Glioblastoma, WHO Grade III Glioma, WHO Grade II Glioma.
What interventions are being tested in trial NCT03251027?
The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION), Quality-of-Life (OTHER).
Who is sponsoring clinical trial NCT03251027?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251027 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03251027's enrollment target sits among peer trials
100 46th of 199 higher than 153 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI